SER-100
Source SER-100 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
SER-100, also known as ZP120, is a synthetic peptide ligand that selectively targets the nociceptin/orphanin FQ (NOP) receptor. It is being explored as a therapeutic candidate for the clinical management of systolic hypertension, based on the role of the NOP system in cardiovascular regulation.
Mechanism of Action
SER-100 binds to the NOP (nociceptin/orphanin FQ) receptor, a G‑protein‑coupled receptor widely expressed in peripheral and central tissues. Activation of this receptor modulates signaling pathways that influence vascular tone, sympathetic outflow, and renal function, thereby affecting systolic blood pressure. The peptide’s design incorporates cyclizations and sequence modifications that enhance selectivity and metabolic stability.
What the Research Shows
The only peer‑reviewed source mentioning SER-100 is a 2019 handbook chapter that reviews NOP‑targeted peptide ligands. It reports that SER-100 (ZP120) has progressed to clinical development for systolic hypertension, alongside other NOP‑focused candidates. The chapter describes extensive structure‑activity relationship work that produced NOP‑selective peptides with improved in‑vivo stability, but it does not provide data from human trials, pre‑clinical efficacy studies, or safety assessments specific to SER-100. Consequently, the published evidence for SER-100 is limited to its identification as a promising NOP‑receptor ligand and its entry into early clinical testing.
Reported Benefits
If efficacy is confirmed, SER-100 could offer a novel mechanism for lowering systolic blood pressure by modulating NOP‑receptor pathways, potentially providing an alternative to existing antihypertensive classes. Its peptide design aims for high receptor selectivity and metabolic stability, which may translate into targeted action with fewer off‑target effects.
Limitations of the Evidence
No clinical trial results, pharmacokinetic data, or safety profiles for SER-100 have been published. The current evidence is confined to pre‑clinical peptide optimization and the statement that the compound is in clinical development. Therefore, its actual antihypertensive efficacy, optimal dosing, and comparative advantage remain unproven.
Safety Considerations
Safety information for SER-100 is not available in the cited literature. As a NOP‑receptor modulator, theoretical concerns include central nervous system effects such as altered pain perception, mood, or autonomic regulation. Until clinical data emerge, potential adverse events and contraindications cannot be defined.
How It Is Administered
The route of administration for SER-100 has not been disclosed in the available abstract. Peptide therapeutics are commonly delivered by injection (intravenous, subcutaneous, or intramuscular) or, less frequently, via intranasal or oral formulations with protective technologies. Formulation details are not provided.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowPreti D, Caló G, Guerrini R2019-01-01T00:00:00.000000Z
- Journal ArticleLowLi X, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleLowShehata SN, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleLowFarajdokht F, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleLowVatandoust SM, Meftahi GH2022-01-01T00:00:00.000000Z
- Journal ArticleLowLangendorf CG, et al.2020-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is SER-100 being developed to treat?
SER-100 is in early clinical development as a candidate for managing systolic hypertension, based on its activity at the nociceptin/orphanin FQ (NOP) receptor.
How does SER-100 differ from traditional antihypertensive drugs?
Unlike most antihypertensives that target the renin‑angiotensin system, calcium channels, or adrenergic receptors, SER-100 modulates the NOP receptor, a distinct pathway that influences vascular tone and sympathetic activity.
Has SER-100 been tested in humans?
The cited literature only notes that SER-100 has entered clinical development; no published human trial results or safety data are available yet.
What are the known side effects of SER-100?
No side‑effect profile has been reported. Potential effects are speculative and would depend on how NOP‑receptor modulation impacts central and peripheral systems.
How is SER-100 administered?
The specific route has not been disclosed. Peptide drugs are typically given by injection, but the exact formulation for SER-100 remains unspecified in the current literature.
What is SER-100?
SER-100, also known as ZP120, is a synthetic peptide ligand that selectively targets the nociceptin/orphanin FQ (NOP) receptor. It is being explored as a therapeutic candidate for the clinical management of systolic hypertension, based on the role of the NOP system in cardiovascular regulation.